CoChat

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence

The DOI matches its Crossref record, with a small difference in title or year; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Long-acting injectable antipsychotics (LAIs) are among the most effective treatments in psychiatry, yet they remain underutilized in clinical practice. Although LAIs are typically used to maintain treatment adherence in patients with chronic schizophrenia, recent research has suggested that they may also provide an effective treatment strategy for patients with early-phase or first-episode disease. In October 2015, a group of 8 experts on the management of schizophrenia and LAIs met to evaluate the evidence surrounding the efficacy, safety, and cost-effectiveness of LAIs and to develop practical recommendations regarding the clinical use, education, and unmet needs related to LAIs. Participants were also asked to rate the importance of several patient characteristics when choosing an LAI versus an oral antipsychotic, from the perspectives of 4 different stakeholder groups: patients, health care professionals, families, and payers. The evidence review demonstrated that LAIs are superior to placebo for acute and maintenance treatment of schizophrenia and, in general, appear to be similar to one another in terms of schizophrenia relapse prevention. Study design impacts the demonstrated efficacy of LAIs versus oral antipsychotics, but recent database and randomized controlled studies favor the use of LAIs in early-phase schizophrenia patients. LAIs vary considerably in their propensity to cause certain adverse effects, including weight gain, metabolic effects, extrapyramidal symptoms, and prolactin elevation, and these differences can be used to help guide LAI selection. Some studies, but not all, have demonstrated significant reductions in health care utilization or overall costs with LAIs. The expert panel identified several barriers to LAI use in current practice, including clinician lack of knowledge, negative attitudes about LAIs, and resource and cost issues. The participants also identified a number of additional factors that should be considered when weighing the use of LAI therapy, including medication adherence, relapse risk and severity, cognitive impairment, ease of use, substance misuse, access and cost, stigma, social support, patient autonomy, control over medication dosing, fear of needles, and the potential for patient harm due to relapses and associated loss of functioning. This evidence review, discussion, and summary recommendations may help clinicians, patients, families, payers, and other stakeholders to better characterize the role of LAIs in the treatment of schizophrenia.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.15032su1

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

The publisher hasn’t deposited this paper’s reference list.

Cited by

Items 201–300 of 372

Metadata

Authors
Correll, C. U., Citrome, L., Haddad, P. M., Lauriello, J., Olfson, M., Calloway, S. M., & Kane, J. M.
Affiliations
  • Hofstra University (US)
  • New York Medical College (US)
  • University of Manchester (GB)
  • University of Missouri (US)
  • Columbia University (US)
  • Missouri Department of Social Services (US)
  • Northwell Health (US)
Venue
The Journal of Clinical Psychiatry
Published
2016-09-30
Volume
77
Issue
Suppl 3
Pages
1-24
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2527103551
Cited by
372
References
0
Citations by year
2026: 28 · 2025: 36 · 2024: 37 · 2023: 54 · 2022: 40 · 2021: 50 · 2020: 36 · 2019: 49 · 2018: 22 · 2017: 20
FWCI
27.00
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
  • Social Sciences › Psychology › Clinical Psychology › Family Caregiving in Mental Illness
Keywords
long-acting injectable antipsychotics, schizophrenia, first-episode schizophrenia, medication adherence, relapse prevention, cost-effectiveness, adverse effects, weight gain, metabolic effects, extrapyramidal symptoms, prolactin elevation, stakeholder perspectives, clinical guidelines
MeSH terms
Chronic Disease, Cost-Benefit Analysis, Delayed-Action Preparations, Humans, Injections, Intramuscular, Mental Health Services, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Utilization Review, Randomized Controlled Trials as Topic, Treatment Outcome, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.